Literature DB >> 27910125

Bioprosthetic tricuspid valve replacement for tricuspid valve endocarditis secondary to infected endocardial pacemaker leads.

Zhiwei Xu1, Qiuxia Shi2, Ju Mei1, Yan Tan3.   

Abstract

BACKGROUND: The purpose of this study was to present outcomes of bioprosthetic tricuspid valve replacement (TVR) in patients with tricuspid valve infective endocarditis (TVIE).
METHODS: From October 2001 to December 2015, 26 patients underwent a bioprosthetic TVR due to severe TVIE after endocardial pacemaker implantation.
RESULTS: Staphylococcus species and Streptococcus species were the predominant microorganisms. Early 30-day hospital mortality was 0 (0%). There were three late deaths (11.5%), none cardiac related. At nine years, freedom from cardiac death was 100%. Mean follow-up was 5.7 ± 4.1 years (range, 1.3-14.2 years). There were two cases (7.7%) of cardiac redo operations related to recurrent infection. At nine years, freedom from valve-related redo operation was 92.3%. There was no thrombosis-embolism, bleeding, or other valve-related events. No peri-valve leak or vegetation was seen on the last echocardiographic examination.
CONCLUSIONS: Bioprosthetic TVR can be performed with acceptable morbidity and mortality in severe tricuspid endocarditis due to infected endocardial pacemaker leads.
© 2016 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2016        PMID: 27910125     DOI: 10.1111/jocs.12878

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  1 in total

1.  Valvectomy versus replacement for the surgical treatment of infective tricuspid valve endocarditis: a systematic review and meta-analysis.

Authors:  Jessica G Y Luc; Jae-Hwan Choi; Karishma Kodia; Matthew P Weber; Dylan P Horan; Elizabeth J Maynes; Laura A Carlson; H Todd Massey; John W Entwistle; Rohinton J Morris; Vakhtang Tchantchaleishvili
Journal:  Ann Cardiothorac Surg       Date:  2019-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.